Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency

NCT03921541 is registered in ClinicalTrials.gov with Immedica Pharma AB as lead sponsor.

NCT NCT03921541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03921541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Lead sponsor
Immedica Pharma AB
Phase
Phase 3
Overall status
Completed
Start date
May 1, 2019
Completion date
February 1, 2023
Enrollment
32 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

arginase i deficiency, hyperargininemia